About

HiFiBiO Therapeutics is a clinical-stage biotech driving a pipeline of transformative immunotherapies.

Vision

Unlock the curative powers of the immune system for each and every patient.

Mission

To build an industry leading biotech to deliver transformative immunotherapies.

Strategy

Advance a pipeline of breakthrough immunotherapies using DIS®, a transformative single-cell translational platform, to improve clinical probability of success.

Our History

Our Story

Publications/Interviews

Drug Discovery Today | Publication | Oct 23, 2024
Drug Intelligence Science (DIS®): Pioneering a high-resolution translational platform to enhance the probability of success for drug discovery and development

Drug Discovery Today | Publication | May 08, 2023
Global or Local: The Future of Biotech

Drug Discovery Today | Publication | Oct 08, 2017
Guiding Principles of Value creation Through Collaborative Innovation in Pharmaceutical Research

NYSE Floor Talk | Interview | Nov 27, 2024
HiFiBiO CEO Liang Schweizer sits down with NYSE Floor Talk on how HiFiBiO is using AI to transform drug development

Nasdaq Live from MarketSite | Interview | Jan 07, 2024
CEO Liang Schweizer Sits with Nasdaq to Share HiFiBiO Therapeutics’ Mission to Unlock the Curative Powers of the Immune System

Biotech2050 | Podcast | Jun 14, 2023
HiFiBiO Therapeutics CEO Liang Schweizer Shares Her Professional Journey and the Company’s Pioneering DIS® Approach on the Biotech2050 Podcast

Life Science Success Podcast | Podcast | Jan 05, 2023
HiFiBiO Therapeutics CEO Liang Schweizer Interviewed by Life Science Success Podcast

Lioness Magazine Interview | Interview | Mar 11, 2021
HiFiBiO Therapeutics CEO Liang Schweizer Interviewed by Lioness Magazine

PharmaBoardRoom Article | Article | Mar 08, 2021
HiFiBiO Therapeutics CEO Liang Schweizer Interviewed by PharmaBoardRoom and Genialis Podcast